Sign up to save your podcasts
Or
Share The Split Vote: UroGen and the FDA
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The Split Vote: UroGen and the FDA
When an FDA panel held her company’s future in the balance, UroGen Pharma CEO Liz Barrett refused to fold, even with the odds stacked, a plunging stock, and one vote deciding it all.
PODCAST TEAM
Producer and Director: Devon Leaver
Editor: Dominique Guerra
Production Coordinator: YingYu Lin
Production Support: Annabelle Chan
Story Consultants: Partner & Research Analyst Tony Nguyen, and Chief Corporate Finance Officer, Chris Seiter.
Featuring: Liz Barrett, President & CEO of UroGen Pharma, moderated by Stephanie A. Sirota, Partner and Chief Business Officer at RTW Investments, LP.
FOLLOW US
Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights.
To make sure you never miss an episode, you can subscribe to the RTW podcast on Spotify, Apple Podcasts, Amazon Music, and most other podcast platforms.
CHAPTERS
00:00 - Introduction
00:54 – Liz Barrett’s pharma journey
03:26 - UroGen: the product and the pipeline
08:31 - The FDA vote on UroGen
15:07 - UroGen and RTW’s relationship
18:42 - Liz Barrett’s leadership style
22:40 - Outro
DISCLAIMER
This interview was given by Liz Barrett, President & CEO of UroGen Pharma, and moderated by Stephanie A. Sirota, Partner and Chief Business Officer at RTW Investments, LP. Statements reflect RTW's views and opinions as of the date hereof and not as of any future date. All expressions of opinion are subject to change without notice and are not intended to be a forecast of future events or results. The views expressed by guests are their own, and their appearance on the program does not imply an endorsement of them or any entity they represent.
View all episodes
By RTW Investments, LPWhen an FDA panel held her company’s future in the balance, UroGen Pharma CEO Liz Barrett refused to fold, even with the odds stacked, a plunging stock, and one vote deciding it all.
PODCAST TEAM
Producer and Director: Devon Leaver
Editor: Dominique Guerra
Production Coordinator: YingYu Lin
Production Support: Annabelle Chan
Story Consultants: Partner & Research Analyst Tony Nguyen, and Chief Corporate Finance Officer, Chris Seiter.
Featuring: Liz Barrett, President & CEO of UroGen Pharma, moderated by Stephanie A. Sirota, Partner and Chief Business Officer at RTW Investments, LP.
FOLLOW US
Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights.
To make sure you never miss an episode, you can subscribe to the RTW podcast on Spotify, Apple Podcasts, Amazon Music, and most other podcast platforms.
CHAPTERS
00:00 - Introduction
00:54 – Liz Barrett’s pharma journey
03:26 - UroGen: the product and the pipeline
08:31 - The FDA vote on UroGen
15:07 - UroGen and RTW’s relationship
18:42 - Liz Barrett’s leadership style
22:40 - Outro
DISCLAIMER
This interview was given by Liz Barrett, President & CEO of UroGen Pharma, and moderated by Stephanie A. Sirota, Partner and Chief Business Officer at RTW Investments, LP. Statements reflect RTW's views and opinions as of the date hereof and not as of any future date. All expressions of opinion are subject to change without notice and are not intended to be a forecast of future events or results. The views expressed by guests are their own, and their appearance on the program does not imply an endorsement of them or any entity they represent.